The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)


Aortic regurgitation assessment using quantitative aortography in transcatheter aortic valve replacement: can this tool have a significant impact on the procedure?

EuroIntervention 2019;15:396-397. DOI: 10.4244/EIJV15I5A72

1. Division of Cardiology, Medical College of Georgia at Augusta University, Augusta, GA, USA; 2. Swedish Heart and Vascular Institute, Seattle, WA, USA; 3. Center for Structural Heart Disease, Henry Ford Health System, Detroit, MI, USA

Transcatheter aortic valve replacement (TAVR) is destined to become commercially available for low-risk surgical patients1,2. However, TAVR is still plagued by transcatheter technology’s inability to completely exclude paravalvular regurgitation (PVR). With the arrival of the newer generation of TAVR devices in the USA, the SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA), the Evolut™ R/PRO (Medtronic, Minneapolis, MN, USA), and the LOTUS Edge™ (Boston Scientific, Marlborough, MA, USA), the incidence of moderate-severe PVR has improved considerably. However, the presence of PVR and, in general, any aortic regurgitation (AR) is associated with increased rates of death and ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from

Read next article

The Atrial Flow Regulator device: expanding the field of interatrial shunting for treating heart failure patients